BioNTech SE (BNTX)

NASDAQHealthcare

$106.97
+$1.15 (+1.1%)
Market closed

February 17, 2026 at 21:00 UTC

Interactive Chart
BNTX
1H
3H
6H
12H
1D
1W
1M
3M
6M
1Y
2Y
5Y
All

01:14:47 UTC

About BioNTech SE

Name

BioNTech SE

CEO

Ugur Sahin

Industry

Healthcare

Year Founded

2008

Employees

6,772

BioNTech SE is a biotechnology company that turns insights in immunology into therapies designed for serious diseases. The model links research platforms with clinical programs and manufacturing methods that can be scaled when evidence supports them. Work spans mRNA and other modalities, but the operating tone stays consistent: design carefully, test with rigor, and communicate results so physicians and regulators can act with confidence. Partnerships extend reach without changing that core rhythm. The goal is to move promising ideas into treatments that fit the routines of modern medicine, with supply and guidance that are as clear as the science behind them.

Analyst Ratings
Consensus Recommendation
Analyst consensus: 15 Buy, 2 Hold, 4 Sell
Buy15
Hold2
Sell4
Fundamentals & Financials
Revenue (TTM)
$3.1B
Net Income (TTM)
-$571.6M
EPS (TTM)
-$2.37
ROA (TTM)
-2.68%
Current Ratio
7.12
Dividend Yield
0.097%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement
ItemQ3 2025
Revenue$1,518.9M
Cost of Sales$148,300K
Gross Profit$1,370.6M
Operating Income-$46,900K
Net Income-$28,700K
EPS-$0.12
Technical Indicators

BioNTech SE's Technical Indicators Summary

BNTX is exhibiting a strong bullish trend, supported by an ADX reading near 28 that indicates solid trend strength. Momentum remains robust, with the MACD and CCI signaling upward movement, even as some oscillators like RSI and MFI suggest overbought conditions. The current price trading well above all major moving averages, including the 200-day SMA and EMA, reinforces the positive price action. Volatility appears steady, with the ATR reflecting moderate daily price swings. Meanwhile, volume-based indicators like OBV confirm buying interest despite a significant negative value. Overall, these factors combine to affirm a sustained bullish technical outlook for BNTX.

Buy
15 signals
Neutral
2 signals
Sell
4 signals
Overall: Bullish71% Bullish signals
IndicatorValue
RSI (14)
70.65
Stochastic %K (14, 3, 3)
88.28
CCI (20)
167.77
WPR (14)
-13.09
Momentum (10)
12.31
MFI
89.10
MACD Level (12, 26)
2.71
Bollinger Bands
$87.38 - $109.57
ATR (14)
$2.86 (2.63%)
ADX (14)
27.81
OBV
-11,026,900
Simple Moving Averages
$98.47 - $102.93(5 indicators)
Exponential Moving Averages
$99.80 - $103.63(5 indicators)
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.

Today's Snapshot

By the end of trading, BNTX had absorbed the small 1.058% gap, settling at 106.99. The day wrapped with earnings still looming for BNTX, 21 days ahead on 2026-03-10. BNTX's stable close amid upcoming earnings suggests cautious investor sentiment ahead of upcoming news.

Price Change

from $105.87 close

+$1.12

Trading Volume

Below avg (738.3K)

370.5K

vs S&P 500 Today

Outperforming Market

+0.97%

52-Week Position

Mid-range

59.6%

Updated: February 17, 2026 at 21:01 UTC

Quote Summary
OpenPrevious Close
$106$105.87
Day Range52 Week Range
$105.48 - $107.56$81.2 - $124.49
VolumeAvg. Volume
369K1.1M
Market CapP/E Ratio
$25.7B-40.5